Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Wednesday, March 15, 2017 at 3:00 pm CET (10:00 am EDT) to discuss the 2016 financial results, as well as provide a fourth quarter business update.
To participate in the conference call, please select your phone number below, and use the confirmation code 75576807. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.
A replay of the webcast will also be available on the argenx website.
About argenx
argenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.
Dial-In Numbers:
Participant Free Call Dial-In Numbers:
UK 0800 694 0257
Participant Standard International Dial-In:
UK Standard International +44 (0) 1452 555 566
Participant UK Local Call Dial-In Numbers:
UK 0844 493 3800
UK National Call 0871 700 0345
Participant Local Call Dial-In Numbers:
Australia 0290 371 687
Austria 0192 865 68
Belgium 0817 000 61
Croatia 0177 766 11
Czech Republic 2288 804 60
Denmark 3272 7625
Finland 0923 195 187
France 0176 742 428
Germany 0692 222 3479
Germany 0692 222 4918
Hungary 0618 088 303
India 0223 098 5304
Ireland 0143 196 48
Ireland 0150 601 53
Italy 0236 008 146
Latvia 6778 2516
Luxembourg 2088 0695
Netherlands 0207 176 886
New Zealand 0992 917 07
Norway 2156 3013
Poland 2230 701 18
Romania 0318 144 957
Russia 4996 771 036
Slovenia 0160 093 64
South Africa 2110 032 02
Spain 9141 436 69
Sweden 0850 336 434
Switzerland 0565 800 007
USA 1631 510 7498
For further information, please contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 243 40 70
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should, and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’ actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. Management’s Discussion and Analysis of Financial Condition and Results of Operations
